Evaxion announces promising results from phase 1/2a clinical trial of personalized dna cancer immunotherapy evx-02

Copenhagen, denmark, nov. 17, 2022 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies, today announced promising clinical data from the phase 1/2a first-in-human study of its dna-based cancer immunotherapy, evx-02.
EVAX Ratings Summary
EVAX Quant Ranking